2020 Revenues ($USD) : $50,446,739,666
2020 Revenues (foreign currencies) : RMB 348,294,380,000
2020 R&D spend : not available
2020 Number of Employees : 108,316
Fiscal Year End : 12/31/2020
Key People : Yu Qingming, chair of the board; Zhou Song, vice president; Liu Yong, president, CEO and executive director; Li Xiaojuan, CFO; Maison Cai, VP; Chen Zhanyu, VP; Jiang Xiuchang, VP; Li Dongjiu, VP; Lian Wanyong, VP; Wang Jie, VP; Xu Shuangjun, VP; Zhou Song, VP; Chang Sing Yuen, joint secretary; Wu Yijian, joint secretary
A nurse holds a vial of Sinopharm COVID-19 vaccine. Image courtesy of Wikipedia.
The Chinese state-owned pharmaceutical giant Sinopharm is a conglomerate with business units spanning R&D, manufacturing, logistics and distribution, retail pharma and beyond. The company boasts that it operates more than 1,100 subsidiaries, including China National Medicines Corp., China National Accord Medicines Corp., Beijing Tiantan Biological Products and Shanghai Shyndec Pharmaceutical. Sinopharm's revenues have expanded significantly in the past decade. Fortune now ranks Sinopharm as the 145th largest company in the world. In 2013, the publication put Sinopharm in slot 446. The company operates a logistics network for drugs and medical devices spanning across China. During the COVID-19 pandemic, the company developed a vaccine that recently received emergency use authorization from the World Health Organization. Sinopharm is the sixth-largest vaccine manufacturer. –BB